# Xingeyuan Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xingeyuan-biotechnology-co

- Industry: Biotechnology
- Headquarters: Nanjing, China
- Website: www.singleronbio.com
- Total disclosed funding: $160M
- Latest round: Series B (Nov 8, 2021)
- Investors on record: 17

## About

Based in Nanjing, China and established in 2018, Xingeyuan Biotechnology Co., Ltd., trading under the name Singleron, operates as a biotechnology company that focuses on developing molecular diagnostic products and automation equipment for clinical application. The company is mainly involved in the field of single-cell multi-omics analysis in drug development, scientific research and genomics industry. The co founder and CEO Dr. Nan Fang is the PhD in Immunology, University of Wolzburg. At present, the company have more than 400 employees, 24 of whom have PhDs. In July 2021, the company launched tissue dissociator Singleron PythoN.

The company self developed products include SCOPE™ single-cell sequencing library construction kits, Matrix® automated single cell processing system, CeleScope™ bioinformatic analysis software, and SynEcoSys® annotation database. Besides, the company provides single-cell transcriptome sequencing, single-cell nuclear transcriptome sequencing, immune receptor sequencing, bio-information analysis services for customer.

The company plans to use the series B funding for product development and global commercialization of high-throughput single-cell multi-omics platform and promote the clinical transformation of innovative single-cell products.

## Funding rounds

- Series B, Nov 8, 2021, $100M — ARCH Venture Partners, CDH Investments, SB China Venture Capital, Lilly Asia Ventures, CDG Invest Growth, MSA Capital, Sherpa Healthcare Partners, Firstlight Capital, Lake Bleu Capital, Superstring Capital Management, CDG Capital, 3W Investment
- Series A, Dec 24, 2020, $30M — CDH Investments, SB China Venture Capital, Lilly Asia Ventures, Tencent Investment, Sherpa Healthcare Partners
- Series A, Nov 11, 2020 — CDH Investments, SB China Venture Capital, Lilly Asia Ventures, CDG Capital
- Series A, Sep 6, 2020, $30M — ARCH Venture Partners, CDH Investments, Lilly Asia Ventures, Tencent Investment, China Growth Capital, Guoxin Guoxin Dongwu Oversea Fund, Sherpa Healthcare Partners
- Angel, May 17, 2018 — Oriza Holdings, Frees Fund

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Angel
- Frees Fund (https://capitalatlas.ai/funds/frees-fund) — Angel
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series A, Series B
- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Series A, Series B
- Tencent Investment — Series A
- China Growth Capital (https://capitalatlas.ai/funds/china-growth-capital) — Series A
- Guoxin Guoxin Dongwu Oversea Fund — Series A
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A, Series B
- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series A, Series B
- CDG Capital (https://capitalatlas.ai/funds/cdg-capital) — Series A, Series B
- CDG Invest Growth (https://capitalatlas.ai/funds/cdg-invest-growth) — Series B
- MSA Capital (https://capitalatlas.ai/funds/msa-capital) — Series B
- Firstlight Capital — Series B
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series B
- Superstring Capital Management (https://capitalatlas.ai/funds/superstring-capital-management) — Series B
- 3W Investment — Series B